Moyamoya Disease Market Size & Share, by Drug Type (Blood Thinners, Calcium Channel Blocker, Anti-Seizure Medications); Diagnosis (Cerebral Angiogram, MRI, MRA, Ct Scan, Transcranial Doppler Ultrasound, Pet Scan, Electroencephalography); Treatment (Surgical, Non-Surgical Treatment); End-User (Hospitals, Pharmacies) - Global Supply & Demand Analysis, Growth Forecasts, Statistics Report 2024-2036

In the News

• Merck's blood vessel disorder therapy receives US FDA's priority review. Merck said on Thursday the U.S. health regulator will review its experimental therapy to treat a type of progressive blood vessel disorder on a priority basis. The drugmaker had gained rights to the therapy, sotatercept, through its USD 11.5 billion acquisition of Acceleron Pharma in 2021. The U.S. Food and Drug Administration has set March 26, 2024 as a target action date for the review, Merck said. If approved, the therapy will help the U.S. drugmaker diversify its revenue stream as its blockbuster cancer immunotherapy, Keytruda, moves towards loss of market exclusivity in 2028.
• Valenta Pharm launches a new generation antioxidant. Ethoxidol – is a new original second generation¹ antioxidant for treatment of chronic ischemia of brain (cerebrovascular failure) introduced Valenta Pharm. Existing antioxidants operating under conditions of ischemia acute at a time of process slow growth can’t unlock own effect. An additional mechanism of an organism adaptation in ischemia slow has inaugurated recently - in the 1990s about. This discovery has led to new medicines development. Ethoxidol – is a second-generation antioxidant for treatment of chronic ischemia of brain. The unique mechanism of Ethoxidol is the distribution of energy inside brain cells and stimulation own antioxidant system of organism. Therefore, we believe that of applications of Ethoxidol will enable the doctors to deal with ischemia acute chronic diseases and will prevent of acute vascular disasters.